FAO Launches Cropsuit App To Help Farmers Grow The Right Crops In The Right Places
July 2026, Rome: Farmers, extension workers and governments now have a powerful new tool to help identify the crops best…
AgriFood Signals: InvestEco closes fourth fund, Bayer consolidates US glyphosate arm, Nestlé ditches artificial colors
AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…
南京农大专利卖5000万；雅苒天禾联合开发包膜肥；中国首个生物刺激素与功能肥部级重点实验室运行 | BioEx情报速览
本周速览：病害防治方面，南京农大专利以5000万元高价转化，Amoéba、GreenLight两款创新生物杀菌剂在欧盟、巴西加速商业化；线虫防治上，植物源纳米乳剂展现出优于传统化学药剂的潜力；生物刺激剂/菌肥领域最为热闹，从新品上市、外资本土化合作到国家级重点实验室落地，多线并进；市场趋势层面，果蔬园艺正成为生物制品出海的高价值赛道。
Nutrition From Water To Take Equity Stake in Algarve Microalgae Firm PhycoFerm
Nutrition from Water (NXW), the New Zealand microalgae ingredients company behind the Marine Whey protein range, has agreed to take an equity stake in PhycoFerm, a strain development and biotechnology company based in Portugal’s Algarve. The investment formalises a joint research strategy between the two and is intended to accelerate NXW’s first and second generations of biological assets. Financial terms were not disclosed.
AstraZeneca returns to CSPC with $1.77bn kidney deal
Why it matters: The agreement adds to a fast-growing relationship between the Cambridge-headquartered pharma and CSPC, and underlines how China-based discovery platforms are becoming a larger part of Big Pharma’s global pipeline sourcing.
FAO Food Price Index Edges Down Amid Diverging Commodity Price Movements
July 2026, Rome: FAO’s benchmark measure of world food commodity prices edged down in June, as lower quotations for cere…
MALK and Coconut Cult Launch Co-Branded Vanilla Coconut Yogurt at Whole Foods
Plant-based milk brand MALK Organics and probiotic yogurt maker The Coconut Cult have released a jointly developed product, the Vanilla MALK Shake, a fermented coconut yogurt reaching Whole Foods Market shelves on July 7.
Oryzon raises €12m to push AML and CNS pipeline
Why it matters: The Barcelona-based company is trying to keep momentum behind two clinical-stage LSD1 inhibitors: iadademstat in haematology and oncology, and vafidemstat in psychiatric and CNS disorders.
Exclusive: ProFuse Technology raises $1.5m to tackle muscle loss in the GLP-1 era
Israeli startup ProFuse Technology—best known for media supplements that optimize muscle tissue formation in cultivated …
Telum raises €18M to push phage-derived antimicrobials toward clinic
Why it matters: Telum is trying to develop a new class of protein-based antimicrobials for infections where traditional antibiotics are losing ground. Its lead programme targets hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii , a difficult-to-treat Gram-negative pathogen linked to multidrug resistance.